Zbigniew Markowski - HELIX BIOPHARMA CEO
HBP Stock | EUR 0.23 0.00 0.00% |
CEO
Dr. Zbigniew Markowski is Chief Executive Officer of the Company. Dr. Markowski comes with a diversified experience having had a career in business university and government. Among others from 2006 until January 10 2016 he served as Chairman of O.M. Finance Ltd a private investment and consulting company from 1998 to 2002 as vicechairman of Prokom Investments SA a Polish investment fund where he was responsible for the financial and pharmaceutical sectors and as Member of the Board of BIOTON SA a pharmaceutical company listed on the Warsaw Stock Exchange from 1993 to 2005 he was a leading coordinator for more than a dozen initial public offerings of Polish companies listed on the WSE. From 1995 he was member or Chairman of the Supervisory Board of many companies listed on the WSE and additionally he served as chairman of the Audit Committees of CIECH SA II NFI SA and ROBYG SA.In 1993 he served as Special Plenipotentiary to the Minister of Privatization and to the Minister of Foreign Trade and in 1994 he was appointed as Commercial Counselor of the Polish People Republic in Stockholm Sweden since 2016.
Tenure | 8 years |
Professional Marks | Ph.D |
Similar Executives
Found 2 records | CEO Age | ||
David Powers | Eagle Materials | 67 | |
Cameron McIntyre | CARSALESCOM | N/A |
HELIX BIOPHARMA Leadership Team
Elected by the shareholders, the HELIX BIOPHARMA's board of directors comprises two types of representatives: HELIX BIOPHARMA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HELIX. The board's role is to monitor HELIX BIOPHARMA's management team and ensure that shareholders' interests are well served. HELIX BIOPHARMA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HELIX BIOPHARMA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Albert Beraldo, Director | ||
Artur Gabor, Director | ||
Steve Demas, COO | ||
Marek Orlowski, Independent Director | ||
Slawomir Majewski, Independent Director | ||
George Anders, Director | ||
Heman Chao, Chief Scientific Officer | ||
Theordore Witek, Director | ||
Zbigniew Markowski, CEO | ||
Sylwester Cacek, Director | ||
Sven Rohmann, Independent Director | ||
Photios Michalargias, CFO | ||
Patrick Frankham, COO |
HELIX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HELIX BIOPHARMA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Current Valuation | 29.03 M | |||
Price To Book | 50.71 X | |||
EBITDA | (6.53 M) | |||
Net Income | (6.56 M) | |||
Cash Flow From Operations | (6.51 M) | |||
Number Of Employees | 13 | |||
Market Capitalization | 38.94 M | |||
Total Asset | 3.73 M | |||
Z Score | -3.3 | |||
Net Asset | 3.73 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards HELIX BIOPHARMA in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, HELIX BIOPHARMA's short interest history, or implied volatility extrapolated from HELIX BIOPHARMA options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HELIX BIOPHARMA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for HELIX Stock analysis
When running HELIX BIOPHARMA's price analysis, check to measure HELIX BIOPHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HELIX BIOPHARMA is operating at the current time. Most of HELIX BIOPHARMA's value examination focuses on studying past and present price action to predict the probability of HELIX BIOPHARMA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HELIX BIOPHARMA's price. Additionally, you may evaluate how the addition of HELIX BIOPHARMA to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
CEOs Directory Screen CEOs from public companies around the world |